Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Proof-of-Concept Trial With Part B and Open-label Extension of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
NCT06018428 is registered in ClinicalTrials.gov with Q32 Bio Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Proof-of-Concept Trial With Part B and Open-label Extension of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
- Lead sponsor
- Q32 Bio Inc.
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- September 12, 2023
- Completion date
- September 30, 2026
- Enrollment
- 75 (estimated)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.